MGMT and glioblastoma: Although MGMT is a well-known biomarker for TMZ resistance in GBMs, combining BICD1 with MGMT expression for risk stratification of GBM patients who received TMZ chemotherapy, may offer more therapeutic information for outcome assessment than MGMT alone.